| CAS No.: | 7491-74-9 |
|---|---|
| Type: | Pharmaceutical Intermediates |
| Appearance: | Powder |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Piracetam |
| CAS | 7491-74-9 |
| MF | C6H10N2O2 |
| MW |
142.16 |
| EINECS |
231-312-7 |
Piracetam is a cyclic derivative of the neurotransmitter gamma-aminobutyric acid(GABA), originally marketed in 1971 by UCB Pharma. It was the first "nootropic" drug, an agent that acts on cognitive function without causing sedation or stimulation. While the mechanisms of action of piracetam have yet to be fully elucidated, it influences neuronal and vascular functions. Furthermore, vascular effects are peripheral as well as central, meaning that the clinical benefit of piracetam goes beyond its nootropic features. Indeed, piracetam is now indicated for use in vertigo, dyslexia, cortical myoclonus and sickle cell anemia in addition to age-related cognitive disorders. Piracetam has been available for over 40 years. Its efficacy has been recorded in cognitive disorders and dementia, vertigo, cortical myoclonus, dyslexia, and sickle cell anemia, however, the clinical application in these conditions is not yet established. Piracetam also has effects on the vascular system through reducing erythrocyte adhesion to vascular endothelium, hinder vasospasm and facilitate microcirculation.Q:How to order a sample for quality testing purpose before your commercial order?
){kind=link}